AU2018310410B2 - Medication for inhibiting DNA-PKcs - Google Patents

Medication for inhibiting DNA-PKcs Download PDF

Info

Publication number
AU2018310410B2
AU2018310410B2 AU2018310410A AU2018310410A AU2018310410B2 AU 2018310410 B2 AU2018310410 B2 AU 2018310410B2 AU 2018310410 A AU2018310410 A AU 2018310410A AU 2018310410 A AU2018310410 A AU 2018310410A AU 2018310410 B2 AU2018310410 B2 AU 2018310410B2
Authority
AU
Australia
Prior art keywords
endostatin
tumor
cell
etoposide
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018310410A
Other languages
English (en)
Other versions
AU2018310410A1 (en
Inventor
Guodong Chang
Lin JIA
Yongzhang Luo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsinghua University
Protgen Ltd
Original Assignee
Tsinghua University
Protgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsinghua University, Protgen Ltd filed Critical Tsinghua University
Publication of AU2018310410A1 publication Critical patent/AU2018310410A1/en
Application granted granted Critical
Publication of AU2018310410B2 publication Critical patent/AU2018310410B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018310410A 2017-07-30 2018-07-27 Medication for inhibiting DNA-PKcs Active AU2018310410B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201710638033 2017-07-30
CN201710638033.2 2017-07-30
CN201710733900 2017-08-24
CN201710733900.0 2017-08-24
PCT/CN2018/097609 WO2019024814A1 (zh) 2017-07-30 2018-07-27 抑制dna依赖蛋白激酶催化亚基的药物

Publications (2)

Publication Number Publication Date
AU2018310410A1 AU2018310410A1 (en) 2020-03-12
AU2018310410B2 true AU2018310410B2 (en) 2024-11-14

Family

ID=65233426

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018310410A Active AU2018310410B2 (en) 2017-07-30 2018-07-27 Medication for inhibiting DNA-PKcs

Country Status (7)

Country Link
US (2) US20200237796A1 (enExample)
EP (1) EP3662922B1 (enExample)
JP (1) JP7492687B2 (enExample)
CN (1) CN110913884B (enExample)
AU (1) AU2018310410B2 (enExample)
CA (1) CA3103035A1 (enExample)
WO (1) WO2019024814A1 (enExample)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1087785A2 (en) 1998-06-15 2001-04-04 Arch Development Corporation Combination of radiotherapy and anti-angiogenic factors
ES2288318T3 (es) 1998-06-30 2008-01-01 Sloan-Kettering Institute For Cancer Research Uso de dna-pk.
US7470667B2 (en) * 2002-12-05 2008-12-30 Medgenn (Hong Kong) Ltd Methods of treating cancer using a modified endostatin protein
US7078485B2 (en) 2002-12-05 2006-07-18 Yantai Medgenn Ltd. N-terminal modified recombinant human endostatin and its production
CN1891717A (zh) * 2005-07-08 2007-01-10 南京大学 内皮抑素的化学修饰方法及其应用
CN100475270C (zh) 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
CN102698270B (zh) * 2011-03-28 2016-02-03 清华大学 一种增强靶细胞摄取治疗剂的方法和药物组合物
WO2013034116A1 (zh) 2011-09-09 2013-03-14 清华大学 对atp结合位点进行突变的血管内皮抑制素突变体

Also Published As

Publication number Publication date
EP3662922A4 (en) 2021-04-07
CN110913884B (zh) 2023-06-06
US20200237796A1 (en) 2020-07-30
AU2018310410A1 (en) 2020-03-12
CA3103035A1 (en) 2019-02-07
JP7492687B2 (ja) 2024-05-30
EP3662922B1 (en) 2025-03-05
JP2020528457A (ja) 2020-09-24
US20240165140A1 (en) 2024-05-23
CN110913884A (zh) 2020-03-24
WO2019024814A1 (zh) 2019-02-07
EP3662922A1 (en) 2020-06-10

Similar Documents

Publication Publication Date Title
Gordon‐Weeks et al. Neutrophils promote hepatic metastasis growth through fibroblast growth factor 2–dependent angiogenesis in mice
JP6956159B2 (ja) 腫瘍溶解性アデノウイルスによる脳癌の処置方法
Kuo et al. STAT3/NF-κB-regulated lentiviral TK/GCV suicide gene therapy for cisplatin-resistant triple-negative breast cancer
Mercurio et al. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model
JP5641927B2 (ja) Ｓｐａｒｃ及びその使用方法
Kang et al. Plasminogen activator inhibitor-1 enhances radioresistance and aggressiveness of non-small cell lung cancer cells
Kurozumi et al. Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61
US9074011B2 (en) Use of PTEN-long leader sequence for transmembrane delivery of molecules
Lee et al. Tissue transglutaminase activates cancer-associated fibroblasts and contributes to gemcitabine resistance in pancreatic cancer
Li et al. Biliverdin protects against cerebral ischemia/reperfusion injury by regulating the miR-27a-3p/Rgs1 axis
Song et al. RNA interference-mediated suppression of TNF-α converting enzyme as an alternative anti-TNF-α therapy for rheumatoid arthritis
Li et al. Enhanced expression of Vastatin inhibits angiogenesis and prolongs survival in murine orthotopic glioblastoma model
US20190388521A1 (en) Reduction of egfr therapeutic toxicity
US20240165140A1 (en) Medication for inhibiting dna-pkcs
US20170281710A1 (en) Use of inhibitors of binding between a par-1 receptor and its ligands for the treatment of glioma
Moxley et al. Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: the search for sensitizing agents
AU2018434924A1 (en) Chemokine responsive activated natural killer cells with secondary homing activation for verified targets
Sanders Modulation of the Immune Response as a Potential Therapeutic for Glioblastoma
WO2024245445A1 (zh) Malt1肿瘤抑制剂、含有其的药物及应用
Thomas EVALUATING EVIDENCE FOR THE USE OF PARP INHIBITORS IN CANCERS WITHOUT BRCA1 OR BRCA2 MUTATIONS
Zhang Antisense Therapy in Mouse Models of Histone H3. 3k27m Diffuse Midline Glioma Inhibits Tumor Growth, Promotes Neural and Glial Differentiation
Cady et al. CSIG-36. NOTCH3 DRIVES MENINGIOMA TUMORIGENESIS AND RESISTANCE TO RADIOTHERAPY
Xiao et al. Synergistic inhibition of APE1 redox activity and ATM activation sensitizes osteosarcoma cells to ionizing radiation by inducing ferroptosis
JP2024058472A (ja) 抗線維化剤、線維症治療用医薬組成物、抗線維化剤の製造方法および抗線維化方法
Zhang et al. CSIG-40. STEAROYL-COA DESATURASE 1 (SCD1) IS REQUIRED FOR WNT SIGNALING TO INDUCE AN APOPTOSIS IN IDH MUTANT GLIOMA

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)